We look forward to further bellwether trials, as they may provide valuable insight into how juries could rule in similar claims involving Risperdal and male breast growth.
New York, NY (PRWEB) May 29, 2015
Johnson & Johnson and its Janssen Pharmaceuticals unit have reached a confidential Risperdal lawsuit (http://www.risperdallawsuit2014.com/) settlement with a California plaintiff who allegedly developed gynecomastia due to his use of the antipsychotic medication. According to court documents, the case had been selected for the third bellwether trial to involve male breast growth allegations in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where more than 1,300 Risperdal claims have been filed. The case was settled on May 28th, just hours before the parties were to present their opening statements. (Case No. 130301812)
“While this settlement is good news for this plaintiff, the litigation involving Risperdal is far from over. Our Firm is representing Risperdal lawsuit plaintiffs in this proceeding who are also alleged to have developed gynecomastia as a result of treatment with this medication. We look forward to further bellwether trials, as they may provide valuable insight into how juries could rule in similar claims involving Risperdal and male breast growth,” said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide Risperdal lawsuit consultations to men and boys who allegedly developed gynecomastia due to their use of the medication.
Risperdal Lawsuit Verdicts
According to court documents, gynecomastia is a condition marked by excessive male breast development. Many of the plaintiffs pursuing such claims in the Pennsylvania Risperdal litigation are alleged to have experienced breast growth severe enough to warrant mastectomy or other surgical intervention to remove excess breast tissue. Their lawsuits accuse Johnson & Johnson and Janssen of concealing information about the drug’s effect on prolactin, a hormone that plays a role in female breast development and lactation. Plaintiffs further allege that the companies improperly marketed Risperdal for off-label uses, including a number of pediatric indications that were not granted regulatory approval until 2006. (In Re: Risperdal Litigation, Case Number 100300296)
Court records indicate that two Risperdal bellwether trials have concluded this year in the Pennsylvania litigation, both of which involved gynecomastia allegations. The first trial ended on February 24th, with the jury awarding $2.5 million to an autistic man who experienced excessive breast growth after taking Risperdal as a child. (Case No. A-196444) The second trial concluded on March 20th, with the jury finding that Johnson & Johnson and Janssen’s warnings about male breast growth were inadequate. However, the plaintiff was not awarded any monetary damages because the panel concluded that he had not proven that Risperdal caused his condition. (Case No. 130301803)
According to court documents, Pennsylvania’s next bellwether trial is scheduled to begin on June 22nd. The Risperdal lawsuit selected for that trial was filed on behalf of a Wisconsin man who is also alleged to have developed gynecomastia due to treatment with the medication. (Case No. 130401984)
Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com